Smith & Nephew SNATS Shares Outstanding 2006-2018 | SNN

Smith & Nephew SNATS shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Smith & Nephew SNATS shares outstanding for the quarter ending June 30, 2018 were 0.000B, a NAN% increase year-over-year.
  • Smith & Nephew SNATS 2017 shares outstanding were 0.438B, a 2.02% decline from 2016.
  • Smith & Nephew SNATS 2016 shares outstanding were 0.447B, a 0.67% decline from 2015.
  • Smith & Nephew SNATS 2015 shares outstanding were 0.45B, a 0% decline from 2014.
Smith & Nephew SNATS Annual Shares Outstanding
(Millions of Shares)
2017 438
2016 447
2015 450
2014 450
2013 453
2012 448
2011 446
2010 444
2009 442
2008 447
2007 462
2006 470
2005 2,345
Smith & Nephew SNATS Quarterly Shares Outstanding
(Millions of Shares)
Q2 2018 0
Q4 2017 0
Q2 2017 0
Q4 2016 0
Q4 2015 0
Q2 2015 0
Q4 2014 449
Q3 2014 447
Q2 2014 447
Q1 2014 446
Q4 2013 450
Q3 2013 452
Q2 2013 454
Q1 2013 453
Q4 2012 449
Q3 2012 447
Q2 2012 446
Q1 2012 447
Q4 2011 446
Q3 2011 443
Q2 2011 445
Q1 2011 446
Q4 2010 444
Q3 2010 457
Q2 2010 445
Q1 2010 442
Q4 2009 441
Q3 2009 441
Q2 2009 443
Q1 2009 445
Q4 2008 445
Q3 2008 463
Q2 2008 444
Q1 2008 441
Q4 2007 451
Q3 2007 406
Q2 2007 470
Q1 2007 469
Q4 2006 464
Q3 2006 2,325
Q2 2006 455
Q1 2006 476
Q4 2005 473
Q3 2005 471
Q2 2005 455
Q1 2005 472
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $16.007B $4.765B
Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $124.342B 19.06
Abbott Laboratories (ABT) United States $122.048B 24.73
Stryker (SYK) United States $62.796B 23.67
Boston Scientific (BSX) United States $50.730B 25.64
Baxter (BAX) United States $33.541B 21.66
Zimmer Biomet Holdings (ZBH) United States $23.031B 14.94
ResMed (RMD) United States $14.492B 27.64
Canopy Growth (CGC) Canada $8.934B 0.00
Perrigo (PRGO) Ireland $8.884B 13.48
Bio-Rad Laboratories (BIO) United States $8.054B 51.50
Aurora Cannabis (ACB) Canada $6.462B 35.26
Hill-Rom Holdings (HRC) United States $6.201B 19.66
Haemonetics (HAE) United States $5.495B 48.33
Insulet (PODD) United States $4.770B 0.00
ICU Medical (ICUI) United States $4.529B 25.23
Hutchison China MediTech (HCM) China $4.274B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.987B 0.00
Agios Pharmaceuticals (AGIO) United States $3.869B 0.00
Neogen (NEOG) United States $3.219B 48.74
National Vision Holdings (EYE) United States $3.101B 61.33
NuVasive (NUVA) United States $2.972B 27.65
Aphria (APHA) $2.572B 0.00
Quidel (QDEL) United States $2.478B 32.30
NxStage Medical (NXTM) United States $1.924B 0.00
Phibro Animal Health (PAHC) United States $1.476B 20.89
AtriCure (ATRC) United States $1.174B 0.00
Cardiovascular Systems (CSII) United States $1.015B 1462.50
VAREX IMAGING (VREX) United States $0.992B 19.93
Meridian Bioscience (VIVO) United States $0.827B 26.35
PetIQ (PETQ) United States $0.803B 22.83
OraSure Technologies (OSUR) United States $0.793B 44.65
Surmodics (SRDX) United States $0.776B 118.55
Eagle Pharmaceuticals (EGRX) United States $0.755B 24.22
Cerus (CERS) United States $0.719B 0.00
MacroGenics (MGNX) United States $0.710B 0.00
Omeros (OMER) United States $0.623B 0.00
Lantheus Holdings (LNTH) United States $0.590B 18.27
Owens & Minor (OMI) United States $0.558B 6.31
Insys Therapeutics (INSY) United States $0.542B 0.00
LeMaitre Vascular (LMAT) United States $0.518B 25.45
NanoString Technologies (NSTG) United States $0.481B 0.00
TG Therapeutics (TGTX) United States $0.438B 0.00
Evolus (EOLS) United States $0.399B 0.00
Quanterix (QTRX) United States $0.359B 0.00
Utah Medical Products (UTMD) United States $0.327B 21.12
Cytosorbents (CTSO) United States $0.302B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.255B 0.00
Surface Oncology (SURF) United States $0.226B 0.00
Rockwell Medical (RMTI) United States $0.211B 0.00
BioLife Solutions (BLFS) United States $0.206B 278.75
Bovie Medical (BVX) United States $0.201B 0.00
Chimerix (CMRX) United States $0.161B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.148B 0.00
Fonar (FONR) United States $0.139B 6.96
Chembio Diagnostics (CEMI) United States $0.104B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.081B 0.00
United-Guardian (UG) United States $0.079B 16.63
Female Health (VERU) United States $0.079B 0.00
Trinity Biotech (TRIB) Ireland $0.077B 24.40
Oramed Pharmaceuticals (ORMP) Israel $0.070B 0.00
InfuSystems Holdings (INFU) United States $0.067B 0.00
CAS Medical Systems (CASM) United States $0.056B 0.00
Neurotrope (NTRP) United States $0.050B 0.00
ImmuCell (ICCC) United States $0.041B 0.00
Capricor Therapeutics (CAPR) United States $0.028B 0.00
Myomo (MYO) United States $0.025B 0.00
Valeritas Holdings (VLRX) United States $0.021B 0.00
Senestech (SNES) United States $0.019B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.019B 0.00
Cellectar Biosciences (CLRB) United States $0.009B 0.00
NeuroMetrix (NURO) United States $0.007B 0.00
Akers Biosciences Inc (AKER) United States $0.000B 0.00